Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of DMR in the Treatment of NASH (DMR_NASH_001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03536650
Recruitment Status : Recruiting
First Posted : May 25, 2018
Last Update Posted : May 28, 2018
Sponsor:
Collaborator:
Fractyl Laboratories, Inc.
Information provided by (Responsible Party):
Erasme University Hospital

Brief Summary:
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of metabolic syndrome and constitutes a serious public health concern manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease. Insuline resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing. Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH. Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications. The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Condition or disease Intervention/treatment Phase
NASH - Nonalcoholic Steatohepatitis Device: DMR Not Applicable

Detailed Description:

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of a metabolic syndrome and constitutes a serious public health concern, manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease.

Insulin resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing.

Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH.

Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications.

The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Design of study The study is designed as a single arm, proof of concept, non-randomized, open label trial to be conducted at one investigational site. All patients with biopsy proven NASH will undergo an upper endoscopy to perform a duodenal mucosal resurfacing procedure. Evolution of liver steatosis (assessed by MRI), insulin resistance (assessed by oral glucose tolerance test), liver damage (evaluated by blood tests), liver elastography (assessed by fibroscan, fibrotest), biometric parameters will be performed pre- and post-procedure.

Primary outcome :

- Feasability and safety of duodenal mucosal resurfacing, using Revita ™ duodenal mucosal resurfacing after submucosal injection, in patients with NASH.

Secondary outcomes:

  • Evolution of steatosis assessed by MRI 6 months after the procedure.
  • Evolution of liver fibrosis (assessed by Fibroscan, Fibrotest, Fibrosis four score (FIB-4) and NAFLD fibrosis score) at 6 and 12 months after the procedure.
  • Evolution of liver tests at 6 and 12 months after the procedure.
  • Evolution of insulin resistance at 1,3,6 and 12 months after the procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study
Actual Study Start Date : November 8, 2017
Estimated Primary Completion Date : June 30, 2018
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Experimental: DMR procedure Device: DMR

Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.

Other Names:

DMR Revita

Other Name: Revita




Primary Outcome Measures :
  1. Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH. [ Time Frame: 12 months ]

    Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.

    Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 months following the intervention.



Secondary Outcome Measures :
  1. Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects. [ Time Frame: baseline and 6 months post-procedure ]
    Magnetic Resonance Fat fraction

  2. Change in NAS score from baseline in the following 12 months in DMR subjects. [ Time Frame: baseline and 12 months post-procedure ]

    Centrally scored histological improvement in NAFLD from baseline to the end of 12 months post-procedure, where improvement is defined as:

    • No worsening in fibrosis; and
    • A decrease in NAFLD Activity Score (NAS) of at least 2 points

  3. Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects [ Time Frame: baseline and 6 months post-procedure ]
    Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.

  4. Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects [ Time Frame: baseline and 12 months post-procedure ]
    Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.

  5. Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects [ Time Frame: baseline and 6 months post-procedure ]
    Transient Elastography

  6. Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects [ Time Frame: baseline and 12 months post-procedure ]
    Transient Elastography

  7. Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects. [ Time Frame: baseline and 12 months post procedure ]
    Magnetic Resonance Fat fraction

  8. Change in transaminases levels from baseline in the following 6 months in DMR subjects [ Time Frame: baseline and 6 months post-procedure ]
    Transaminases levels

  9. Change in transaminases levels from baseline in the following 12 months in DMR subjects [ Time Frame: baseline and 12 months post-procedure ]
    Transaminases levels

  10. Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects [ Time Frame: baseline and 6 months post-procedure ]
    Insulin resistance as abnormal HOMA IR

  11. Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects [ Time Frame: baseline and 12 months post procedure ]
    Insulin resistance as abnormal HOMA IR

  12. Change in stage of fibrosis from baseline in the following 12 months in DMR subjects [ Time Frame: baseline and 12 months post-procedure ]
    Liver histology



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   28 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult subjects (male and female), age 28 to 75 years.
  2. NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree> 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study and confirmed by central reading during the periode and (apendix 1)

    1. SAF (steatosis, activity, fibrosis) activity score of 3 or 4 (>2)
    2. SAF steatosis score ≥ 1
    3. SAF fibrosis score < 4
  3. No other causes of chronic liver disease and compensated liver disease.
  4. If applicable, have a type 2 diabetes with HbA1c <10.0 %
  5. BMI (body mass index) ≥ 24 and ≤ 40 kg/m2.
  6. Willing to sign an informed consent form.
  7. Willing to comply with study requirements

Exclusion Criteria:

  1. Evidence of another cause of liver disease.
  2. History of sustained alcohol ingestion defined as: daily alcohol consumption > 30 g/day for males and > 20 g/day for females.
  3. Previous gastrointestinal surgery such as subjects who have had Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions.
  4. Known autoimmune disease, including celiac disease, or symptoms of systemic lupus eythematosus, sleroderma or other auto-immune connective tissue disorder.
  5. For type 2 diabetes subjects, no current use of insulin or GLP-1 analogues.
  6. Type 1 diabetes.
  7. Probable insulin production failure defined as fasting C peptide serum < 1 ng/ml.
  8. History of acute or chronic pancreatitis.
  9. Active malignancy.
  10. Persistent anemia defined as Hb < 10 g/dl.
  11. Use of anticoagulation therapy which cannot be discontinued for 7 days before and 14 days after the procedure.
  12. Use of P2Y12 inhibitors (clopidrogel, prasugrel, ticagrelor) which cannot be discontinued for 14 days before and14 days after the procedure.
  13. History of coagulopathy or upper gastro-intestinal bleeding conditions likely to bleed.
  14. Taking corticosteroids or drugs which possibly affect gastrointestinal motility or liver.
  15. Unable to discontinue NSAIDs (non-steroidal anti- inflammatory drugs) during the treatment up to 4 weeks after procedure.
  16. Use of weight loss medications.
  17. Presence of liver cirrhosis (defined by histology)
  18. Platelet count < 120 x 109/L.
  19. Clinical evidence of hepatic decompensation or severe liver impairment as defined by the presence of any of the following abnormalities:
  20. Serum albumin < 32 g/L.
  21. INR> 1.3.
  22. Direct bilirubin> 1.3 mg/L.
  23. ALT or AST > 5x ULN.
  24. Alkaline Phosphatase > 3x ULN.
  25. History of esophageal varices, ascites or hepatic encephalopathy.
  26. Splenomegaly.
  27. Human immunodeficiency virus.
  28. Contraindications to MRI as defined below.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03536650


Contacts
Layout table for location contacts
Contact: Alia Hadefi, MD +3225553714 alia.hadefi@erasme.ulb.ac.be
Contact: Christophe Moreno, PhD, MD +3225553714 christophe.moreno@erasme.ulb.ac.be

Locations
Layout table for location information
Belgium
Erasme Hospital Recruiting
Brussels, Belgium, 1070
Contact: Mona Hammam    +32 2 555 47 64    mona.hammam@erasme.ulb.ac.be   
Principal Investigator: Jacques Deviere, MD,PhD         
Sub-Investigator: Christophe Moreno, MD, PhD         
Sponsors and Collaborators
Erasme University Hospital
Fractyl Laboratories, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jacques Deviere, PhD, MD Erasme Hospital

Publications:

Layout table for additonal information
Responsible Party: Erasme University Hospital
ClinicalTrials.gov Identifier: NCT03536650     History of Changes
Other Study ID Numbers: P2017/302
First Posted: May 25, 2018    Key Record Dates
Last Update Posted: May 28, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Erasme University Hospital:
Metabolic diseases

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases